Bibliography
- Dustin ML, Rothlein R, Bhan AK, et al. Induction by IL 1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J Immunol 1986;137(1):245-54
- Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood 1994;84(7):2068-101
- Albelda SM, Smith CW, Ward PA. Adhesion molecules and inflammatory injury. FASEB J 1994;8(8):504-12
- Ding ZM, Babensee JE, Simon SI, et al. Relative contribution of LFA-1 and Mac-1 to neutrophil adhesion and migration. J Immunol 1999;163(9):5029-38
- Nagata M, Sedgwick JB, Kita H, Busse WW. Granulocyte macrophage colony-stimulating factor augments ICAM-1 and VCAM-1 activation of eosinophil function. Am J Respir Cell Mol Biol 1998;19(1):158-66
- Horie S, Okubo Y, Hossain M, et al. Intercellular adhesion molecule-1 on eosinophils is involved in eosinophil protein X release induced by cytokines. Immunology 1997;90(2):301-7
- Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354(9):899-910
- Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003;349(21):2004-13
- Arndt H, Palitzsch KD, Grisham MB, Granger DN. Metronidazole inhibits leukocyte-endothelial cell adhesion in rat mesenteric venules. Gastroenterology 1994;106(5):1271-6
- Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005;353(18):1912-25
- Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005;352(24):2499-507
- Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004;126(6):1504-17
- Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348(7):601-8
- Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007;146(12):829-38
- Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004;126(2):402-13
- Hurst RD, Molinari M, Chung TP, et al. Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy. Arch Surg 1996;131(5):497-500
- Meenan J, Mevissen M, Monajemi H, et al. Mechanisms underlying neutrophil adhesion to apical epithelial membranes. Gut 1996;38(2):201-5
- Parkos CA, Colgan SP, Diamond MS, et al. Expression and polarization of intercellular adhesion molecule-1 on human intestinal epithelia: consequences for CD11b/CD18-mediated interactions with neutrophils. Mol Med 1996;2(4):489-505
- Vainer B, Nielsen OH. Changed colonic profile of P-selectin, platelet-endothelial cell adhesion molecule-1 (PECAM-1), intercellular adhesion molecule-1 (ICAM-1), ICAM-2, and ICAM-3 in inflammatory bowel disease. Clin Exp Immunol 2000;121(2):242-7
- Patel RT, Pall AA, Adu D, Keighley MR. Circulating soluble adhesion molecules in inflammatory bowel disease. Eur J Gastroenterol Hepatol 1995;7(11):1037-41
- Jones SC, Banks RE, Haidar A, et al. Adhesion molecules in inflammatory bowel disease. Gut 1995;36(5):724-30
- Crooke ST. Progress in antisense technology. Ann Rev Med 2004;55:61-95
- Wu H, Lima WF, Zhang H, et al. Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs. J Biol Chem 2004;279(17):17181-9
- Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, et al. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 1998;114(6):1133-42
- Yacyshyn BR, Barish C, Goff J, et al. Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease. Aliment Pharmacol Ther 2002;16(10):1761-70
- Miner PB Jr, Geary RS, Matson J, et al. Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis. Aliment Pharmacol Ther 2006;23(10):1427-34
- Yacyshyn B, Chey WY, Wedel MK, et al. A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease. Clin Gastroenterol Hepatol 2007;5(2):215-20
- Schreiber S, Nikolaus S, Malchow H, et al. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Gastroenterology 2001;120(6):1339-46
- Van Deventer SJ, Tami JA, Wedel MK. A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis. Gut 2004;53(11):1646-51
- Henry SP, Denny KH, Templin, et al. Effects of an antisense oligonucleotide inhibitor of human ICAM-1 on fetal development in rabbits. Birth Defects Res B Dev Reprod Toxicol 2004;71(6):368-73
- Henry SP, Denny KH, Templin MV, et al. Effects of human and murine antisense oligonucleotide inhibitors of ICAM-1 on reproductive performance, fetal development, and post-natal development in mice. Birth Defects Res B Dev Reprod Toxicol 2004;71(6):359-67
- Bennett CF, Kornbrust D, Henry S, et al. An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice. J Pharmacol Exp Ther 1997;280(2):988-1000
- Yacyshyn BR, Chey WY, Goff J, et al. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut 2002;51(1):30-6
- Yacyshyn BR, Schievella A, Sewell KL, Tami JA. Gene polymorphisms and serological markers of patients with active Crohn's disease in a clinical trial of antisense to ICAM-1. Clin Exp Immunol 2005;141(1):141-7
- Van Deventer SJ, Wedel MK, Baker, et al. A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis. Aliment Pharmacol Ther 2006;23(10):1415-25
- Miner PB Jr, Wedel MK, Xia S, Baker BF. Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial. Aliment Pharmacol Ther 2006;23(10):1403-13
- Miner P, Wedel M, Bane B, Bradley J. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis. Aliment Pharmacol Ther 2004;19(3):281-6
- Maksymowych WP, Blackburn WD Jr, Tami JA, Shanahan WR Jr. A randomized, placebo controlled trial of an antisense oligodeoxynucleotide to intercellular adhesion molecule-1 in the treatment of severe rheumatoid arthritis. J Rheumatol 2002;29(3):447-53
- Forbes E, Hulett M, Ahrens R, et al. ICAM-1-dependent pathways regulate colonic eosinophilic inflammation. J Leukoc Biol 2006;80(2):330-41
- Miner PB, Wedel M. Response of the gastrointestinal & pulmonary symptoms of Churg-Strauss syndrome (CSS) to treatment with an antisense inhibitor to ICAM-1 (alicaforsen). Am J Gastroenterology 2004;99(10):S172(A527)